Optimisation of a primary human CAR‐NK cell manufacturing pipeline
Clinical & Translational Immunology · 2024-01 · 13 (5)
DOI: 10.1002/cti2.1507 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical & Translational Immunology, online erschienen am 02.05.2024. Verfasst von Aline Pfefferle und 11 weiteren Autor:innen. Beteiligte Einrichtung: Biomedicine Discovery Institute and the Department of Biochemistry and Molecular Biology Monash University Clayton VIC Australia. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Autologous chimeric antigen receptor (CAR) T‐cell therapy of B‐cell malignancies achieves long‐term disease remission in a high fraction of patients and has triggered intense research into translating this successful approach into additional cancer types. However, the complex logistics involved in autologous CAR‐T manufacturing, the compromised fitness of patient‐derived T cells, the high rates of serious toxicities and the overall cost involved with product manufacturing and hospitalisation have driven innovation to overcome such hurdles. One alternative approach is the use of allogeneic natural killer (NK) cells as a source for CAR‐NK cell therapy. However, this source has traditionally faced numerous manufacturing challenges.
Methods
To address this, we have developed an optimised expansion and transduction protocol for primary human NK cells primed for manufacturing scaling and clinical evaluation. We have performed an in‐depth comparison of primary human NK cell sources as a starting material by characterising their phenotype, functionality, expansion potential and transduction efficiency at crucial timepoints of our CAR‐NK manufacturing pipeline.
Results
We identified adult peripheral blood‐derived NK cells to be the superior source for generating a CAR‐NK cell product because of a higher maximum yield of CAR‐expressing NK cells combined with potent natural, as well as CAR‐mediated anti‐tumor effector functions.
Conclusions
Our optimised manufacturing pipeline dramatically improves lentiviral transduction efficiency of primary human NK cells. We conclude that the exponential expansion pre‐ and post‐transduction and high on‐target cytotoxicity make peripheral blood‐derived NK cells a feasible and attractive CAR‐NK cell product for clinical utility.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Biomedicine Discovery Institute and the Department of Biochemistry and Molecular Biology Monash University Clayton VIC Australia.
- oNKo-Innate Pty Ltd Moonee Ponds VIC Australia.
- CIRI, Université de Lyon, INSERM U1111, ENS de Lyon Université Lyon 1, CNRS, UMR 5308 Lyon France.
- INSERM, C3M Université Côte d'Azur Nice France.
- Kite Pharma, a Gilead Company Santa Monica CA USA.
ORCID-Profile: Aline Pfefferle, Nicholas D Huntington
Zitieren
APA
Pfefferle, A., Contet, J., Wong, K., Chen, C., Verhoeyen, E., Slichter, C. K., Schluns, K. S., Cursons, J., Berry, R., Nikolic, I., Rautela, J., & Huntington, N. D. (2024). Optimisation of a primary human CAR‐NK cell manufacturing pipeline. Clinical & Translational Immunology, 13(5). https://doi.org/10.1002/cti2.1507
Vancouver
Pfefferle A, Contet J, Wong K, Chen C, Verhoeyen E, Slichter CK, et al. Optimisation of a primary human CAR‐NK cell manufacturing pipeline. Clinical & Translational Immunology. 2024;13(5). doi:10.1002/cti2.1507
BibTeX
@article{Pfefferle2024,
author = {Pfefferle, Aline and Contet, Julian and Wong, Kahlia and Chen, Charlotte and Verhoeyen, Els and Slichter, Chloe K and Schluns, Kimberly S and Cursons, Joseph and Berry, Richard and Nikolic, Iva and Rautela, Jai and Huntington, Nicholas D},
title = {Optimisation of a primary human CAR‐NK cell manufacturing pipeline},
journal = {Clinical & Translational Immunology},
year = {2024},
volume = {13},
number = {5},
doi = {10.1002/cti2.1507}
}
EUVIMED